Neoplasms Clinical Trials in New Haven, Connecticut

4 studies are recruiting for neoplasms in New Haven, Connecticut right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells

   This is a prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult participants exposed to Gene-modified (GM) T-cell therapy participating in a previous Celgene sponsored or Celgene alliance partner sponsored study. Participants who received at least o…

   Stage

   Phase 2

   Ages

   Any age

   Site

   Yale Cancer Center, New Haven, Connecticut

   Locations

   222 in total

   Run by

   Celgene

   See if you can join NCT03435796 on ClinicalTrials.gov

2. A Study of [18F]LY4214835 in Healthy Volunteers and Participants With Cancer

   The purpose of the study is to check how safe and well-tolerated [18F]LY4214835 injection is in healthy participants and participants with cancer. The study drug will be administered intravenously (IV) (into a vein). Participation in the study will last approximately 35 days.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Invicro, New Haven, Connecticut

   Locations

   6 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT07258836 on ClinicalTrials.gov

3. A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)

   The goal of this study is to assess the safety, tolerability, clinical activity and pharmacokinetics of Risvutatug rezetecan (Ris-Rez), also known as GSK5764227. The study will also see how the levels of Ris-Rez will change over time at different dose amounts when administered alone and in combinat…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   GSK Investigational Site, New Haven, Connecticut

   Locations

   67 in total

   Run by

   GlaxoSmithKline

   See if you can join NCT06551142 on ClinicalTrials.gov

4. A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)

   This study aims to evaluate the safety and tolerability of RO7673396 in participants with advanced solid tumors harboring RAS mutation(s). This study consists of two stages: Stage 1 (Dose Escalation) and Stage 2 (Dose Expansion). Stage 1 will define the recommended dose(s) for expansion (RDEs) of R…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Smilow Cancer Hospital at Yale New Haven, New Haven, Connecticut

   Locations

   21 in total

   Run by

   Hoffmann-La Roche

   See if you can join NCT06884618 on ClinicalTrials.gov